Hypercholesterolemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hypercholesterolemia Market Outlook

Thelansis’s “Hypercholesterolemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypercholesterolemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypercholesterolemia Overview

Lipoprotein disorders are clinically significant due to their role in atherogenesis and the associated risk of atherosclerotic cardiovascular disease (ASCVD). In patients with established ASCVD (secondary prevention), cholesterol-lowering interventions consistently reduce cardiovascular mortality and events across genders and age groups. Lipoproteins, composed of lipids and proteins, transport cholesterol, triglycerides, and fat-soluble vitamins in plasma to various organs. High cholesterol is defined as LDL-cholesterol levels exceeding 190 mg/dL, greater than 160 mg/dL with one significant risk factor, or greater than 130 mg/dL with two cardiovascular risk factors. Key risk factors include age (≥45 years for males, ≥55 years for females), a positive family history of premature ASCVD (onset before 55 years in males and 65 years in females), hypertension, diabetes, smoking, and low HDL-cholesterol levels (<40 mg/dL in males and <55 mg/dL in females). Familial hypercholesterolemia involves defects or absence of the LDL receptor, impairing hepatic cholesterol uptake. The liver typically processes two-thirds of circulating LDL. Numerous mutations in the LDL receptor gene manifest as hypercholesterolemia. The cornerstone of hypercholesterolemia management includes a healthy lifestyle, maintaining optimal weight, smoking cessation, 150 minutes of weekly exercise, and a diet low in saturated and trans fats and rich in fiber, fruits, vegetables, and fatty fish. Plant stanols (2 g/day) can reduce LDL-C levels. Statins, the preferred drug class, lower LDL-C by 22% to 50% and reduce cardiovascular events in primary and secondary prevention trials. Significant side effects include elevated transaminases, myalgia, myopathy, and new-onset diabetes. If transaminases exceed three times the upper limit of normal, the statin dose should be reduced or switched. Myopathy, a severe complication, can lead to rhabdomyolysis and acute renal failure. The risk increases with certain drugs, including gemfibrozil, macrolide antibiotics, azole antifungals, protease inhibitors, cyclosporine, nefazodone, other CYP3A4 inhibitors, and multisystem diseases. Some patients may require additional drugs to achieve adequate LDL-C control despite high-dose statin therapy. Cholesterol absorption inhibitors (e.g., ezetimibe) and bile acid sequestrants are next-line therapies due to their safety in combination with statins. Niacin can further lower LDL-C in primary prevention but is not recommended for patients with ASCVD.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: